AstraZeneca has started patient recruitment in Kodiac Phase III clinical trial in the US to evaluate the safety and efficacy of an experimental drug as a treatment for opioid-induced constipation (OIC).
Subscribe to our email newsletter
Kodiac program includes two placebo controlled randomized Phase III studies and a randomized, open-label, placebo-controlled long term safety study.
The two studies are designed to investigate the safety, efficacy and tolerability of an experimental drug as a treatment for OIC.
AstraZeneca Clinical Research senior director Jaakko Lappalainen said the Kodiac study is a clinical trial being conducted to help determine whether AstraZeneca’s investigational drug may be helpful in treating this medical problem.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.